TransCode Therapeutics says Australia accepts patent application for siRNA cancer nanoparticle delivery

TransCode Therapeutics reported patent progress in Australia, citing acceptance of an application covering siRNA cancer therapies using nanoparticle delivery.

Japan granted a patent covering RNA immunomodulatory compositions designed to activate innate immune pathways such as RIG-I in tumors.

The Australian application covers iron-oxide, dextran-coated nanoparticles with covalently linked siRNA, spanning broad oncology use.

Japanese claims include approaches aimed at cancers expressing miR-21, including nanoparticle-enabled delivery systems.

The Australian patent, if granted, is expected to expire on Sept. 6, 2039.